Trial Profile
An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Mycophenolate mofetil (Primary) ; Prednisone (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Roche
- 16 May 2016 Time frame of the primary end point is changed to 2 years.
- 23 Jul 2009 New source identified and integrated (Roche).
- 17 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.